Kornimate/medical-research-clean huggingface dataset:
ar training platform at home

Conditions: Stroke; Chronic Disease

Summary: video communications, like zoom, have been widely used in the time of this epidemic. but how about to design an ar / vr communication system with coaching from clinician to facilitate training at home in this time of epidemic. vulnerable individuals at home can interact with the training platform and his/her clinician can provide online training progamme with guidance.


Eligibility criteria:
inclusion criteria: 1. age \>=65 years old or suffering from chronic disease; 2. sufficient cognition to follow simple instructions as well as understand the content and purpose of the study moca\> 21); and 3. home setting: tv with hdmi input, internet access, and a distance of 1.5m away from tv. exclusion criteria: 1. any additional medical or psychological condition that would affect their ability to comply with the study protocol, e.g., a significant orthopaedic or chronic pain condition, major post-stroke depression, epilepsy, artificial cardiac pacemaker / joint; 2. severe shoulder or arm contracture/pain; 3. severe knee or hip contracture/pain; 4. pregnant women
large macular hole closure rate with amniotic membrane graft with and without limitorrhexis

Conditions: Macular Holes

Summary: patients with idiopathic macular holes (mhs) postoperative closure rates for large mhs (diameter \> 550 μm) are disappointing and often require a second intervention, different techniques have been described with very variable success rates in different published studies, an efficient technique with good functional outcome has not been found.

interventional study in large macular holes (diameter \> 550 μm) using an amniotic membrane with and without internal limiting membrane peeling.

Eligibility criteria:
inclusion criteria: * not myopic patients (\<6 dioptre or \<26 mm) * large macular hole \>550 μm * \> 6 months symptoms * signing informed consent exclusion criteria: * patients with other ocular disease (diabetic retinopathy, glaucoma, uveitis, ocular tumors, etc) * using systemic drugs that are toxic for the optic nerve or retina (chloroquine, hydroxychloroquine, tamoxifen, ethambutol, etc) * patients with ocular surgery
induced pluripotent stem cells for niemann pick disease

Conditions: Niemann-Pick Diseases

Summary: establishment of individualized human cellular disease models based on induced pluripotent stem cells that reflect the broad heterogeneous phenotypic spectrum of niemann pick disease

niemann-pick disease type c (npc) is a lipid storage disease that can present in infants, children, or adults. neonates can present with ascites and severe liver disease from infiltration of the liver and/or respiratory failure from infiltration of the lungs. other infants, without liver or pulmonary disease, have hypotonia and developmental delay. the classic presentation occurs in mid-to-late childhood with the insidious onset of ataxia, vertical supranuclear gaze palsy, and dementia. dystonia and seizures are common. dysarthria and dysphagia eventually become disabling, making oral feeding impossible; death usually occurs in the late second or third decade from aspiration pneumonia. adults are more likely to present with dementia or psychiatric symptoms. the diagnosis of npc is confirmed by biochemical testing that demonstrates impaired cholesterol esterification and positive filipin staining in cultured fibroblasts. biochemical testing for carrier status is unreliable. most individuals with npc have npc1, caused by mutations in the npc1 gene; fewer than 20 individuals have been diagnosed with npc2, caused by mutations in the npc2 gene. molecular genetic testing of the npc1 genes detects disease-causing mutations in approximately 94% of individuals with npc. such testing is available clinically. npc is inherited in an autosomal recessive manner. the phenotype (i.e., age of onset and severity of symptoms) usually runs true in families. carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible when the two disease-causing mutations have been identified in the family. though npc is a pan-ethnic disorder, the prevalence of this autosomal-recessive disorder is elevated in countries with a higher frequency of consanguinity. therefore, the goal of the study to prepare a cell culture from patients affected with niemann pick disease in order to identify novel pathways and proteins involved in disease progression that allow for an earlier diagnosis (i.e. before symptom onset) and that are suitable targets for an individualized therapeutic approach able to address not only the hepatic form, but also the neurologic form of the disease, which is less responsive to the current therapeutic approaches.

Eligibility criteria:
inclusion criteria: * informed consent will be obtained from the patient or the parents before any study related procedures * patients of both genders older than 6 months and younger than 80 years * the patient has a diagnosis of niemann pick disease exclusion criteria: * no informed consent from the patient or the parents before any study related procedures * patients of both genders younger than 6 months or older than 80 years * no diagnosis of niemann pick disease
training in the 21st century: using virtual role-plays to improve nurse communication for medication adherence

Conditions: High Blood Pressure; Hypertension

Summary: this study will utilize a three-phase approach that is informed by a theory-driven implementation framework to: 1) conduct a needs analysis in order to identify individual-, health care team-, and practice-level barriers and facilitators to conducting adherence counseling in safety-net primary care practices; 2) develop a virtual communication simulation designed to improve the quality of adherence counseling by allowing nurses repeated opportunities to practice discussing medication adherence with virtual patients; and 3) conduct a pilot study to evaluate the feasibility, acceptability and preliminary efficacy of the simulation on changes in: a) nurses' collaborative communication skills, b) medication adherence, and c) reduction in bp in a sample of 20 patients with uncontrolled hypertension (htn) who are non-adherent to their medications.


Eligibility criteria:
inclusion criteria: * pcps and nurses will be enrolled if they fulfill the following criteria: 1. male or female healthcare provider (md/do, np, and registered nurse) practicing at the clinic 2. age 18 years or older. no exclusions will be made based on provider race/ethnic origin. we will oversample males to examine differential communication skills based on gender. * patient eligibility criteria include: 1. receiving care at the participating clinic 2. having uncontrolled htn (bp\>140/90 mmhg) at two visits in the past year 3. being prescribed at least one antihypertensive medication and are non-adherent 4. are ≥age 18 years 5. fluent in english exclusion criteria: * unable to give consent * have a diagnosis of cognitive dysfunction or significant psychiatric comorbidity, * participating in another htn-related study.
ultrasound findings of finger, wrist and knee joints in mucopolysaccharidosis

Conditions: MPS I; MPS IV

Summary: hardly any imaging studies specifically addressing the articular and periarticular structures in mps patients are available at this point. the investigators propose to do for the first time a pilot study using musculoskeletal ultrasound in patients with various types of mps.


Eligibility criteria:
inclusion criteria * diagnosis of mucopolysaccharidosis * ability to collaborate with the ultrasound assessment * written informed consent from parents and patients over 14 years of age, assent from children 7 to 14 years exclusion criteria * inability to collaborate with the ultrasound assessment * acute trauma to a joint that will be assessed in the 3 months preceding the study * coexistence of other pathology that is known to affect the respective joints
phase i rindopepimut after conventional radiation in children w/ diffuse intrinsic pontine gliomas

Conditions: Brain Cancer; Brain Stem Tumors; Pontine Tumors

Summary: this is a research study of patients with diffuse intrinsic pontine gliomas. we hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the egfrviii peptide vaccine after conventional radiation.


Eligibility criteria:
inclusion criteria: 3.1.1 patients must be at least 3 years of age and ≤ 18 years of age at the time of study enrollment. 3.1.2 patients must have clinical findings and neuroradiographic findings consistent with diffuse intrinsic pontine glioma. histologic confirmation of diagnosis is not required for diffuse intrinsic pontine gliomas. a copy of the mri must be submitted for verification of eligibility. 3.1.3 patients must have received conventional radiation therapy of total radiation dosage ranging from 5400 to 6000 cgy administered in fractions of 150 to 200 cgy over 6 weeks. 3.1.4 treatment must start 14 to 28 days after completion of conventional radiation 3.1.5 patients receiving systemic corticosteroid therapy must be on a tapering or stable low (2 mg twice daily) dose of dexamethasone two weeks after conventional radiation. 3.1.6 patients life expectancy must be greater or equal to 8 weeks. 3.1.7 patients must have a performance status (lansky or karnofsky) ≥ 50. 3.1.8 platelet count ≥ 100,000/ mm3. 3.1.9 hemoglobin ≥ 10 g/dl. 3.1.10 creatinine ≤ 2.0 mg/dl. 3.1.11 serum bilirubin ≤ 5.0 mg/dl. 3.1.12 if female, patients of childbearing potential must have a negative serum β-hcg pregnancy test. 3.1.13 both male and female patients must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the study. 3.1.14 the patient and/or their guardian must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria 3.2.1 prior therapy for diffuse intrinsic pontine glioma, aside from surgery, conventional radiation, and temozolomide. 3.2.2 use of any experimental drug for any reason within the 60 days prior to treatment. 3.2.3 active infection requiring treatment. 3.2.4 known medical condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study. this would include chronic active hepatitis infection, known immunosuppressive disease or concurrent neurodegenerative disease. 3.2.5 known allergy or hypersensitivity to any of the components of the vaccine treatment, including gm-csf, yeast derived products, or a history of anaphylactic reactions to shellfish proteins. 3.2.6 pregnant women and women who are breast-feeding.
relation between microrna 203 and 210 and sparing the laparoscopic examination in cases of unexplained infertility

Conditions: Infertility Unexplained; Endometriosis

Summary: the study targets to evaluate the role of estimation of plasma expression levels of gene of micrornas 203 and 210 in helping to diagnose and grade endometriosis. the study included women with unexplained infertility and clinical picture suggestive of presence of endometriosis were divided randomly into two groups: control and study groups. all patients underwent exploratory laparotomy for diagnosis and grading of endometriosis if present. patients of study group gave blood samples for estimation of plasma expression levels of microrna 203 and 210 using qrt-pcr procedure.


Eligibility criteria:
inclusion criteria: * 30-45 years old * unexplained infertility exclusion criteria: * presence of other causes of infertility, * age out of the predetermined range, * the presence of immune disorders, * maintenance on immunosuppressive drugs
efficacy of cerave® moisturizing cream on skin pruritus in elderly patients

Conditions: Pruritus

Summary: the goal of this clinical trial is to evaluate the cerave® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. the main questions it aims to answer are: type of study: clinical trial participant population:in patients with chronic elderly pruritus \[question 1\] evaluate the cerave® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors. \[question 2\] evaluate the tolerance of cerave® moisturising cream. \[question 3\] evaluate the product experience of patients who were utilizing cerave® moisturising cream. this trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating cerave® moisturising cream ) and control side (applicating standard cream)according to random number representation. grouping results were double-blinded.


Eligibility criteria:
inclusion criteria: * patients age≥60 years old(male or female). * clinician evaluates dry pruritus or patient complains of pruritus, which lasts for more than 1 month. * patients informed consent to the purpose and content of the research, willing to cooperate with follow-up observation. have good communication and understanding skills. * patients are willing to share photos for medical research purpose. exclusion criteria: * patients with bacterial and/or viral infections in the acute phase of skin inflammation * the affected area is complicated by other skin diseases that may affect the efficacy evaluation * those who are allergic to the ingredients of this product or with allergic constitution * patients who have severe heart, brain, lung, or liver damage. * those who have received systemic or local antiallergic drug treatment within 2 weeks before enrollment of this study. * those who attending other clinical drug trials within 4 weeks before enrollment of this study. * patients with a history of alcohol or drug abuse. * patients who are unwilling to sign the informed consent form, and those who are unwilling to cooperate.
gped for patients with relapsed/refractory or advanced nk/t-cell lymphoma

Conditions: Extranodal NK/T-cell Lymphoma

Summary: the purpose of this study is to evaluate the efficacy and safety of gped (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of relapsed/refractory or advanced nk/t-cell lymphoma patients


Eligibility criteria:
inclusion criteria: histopathology and immunohistochemistry confirmed diagnosis of nk/tcell lymphoma according to who 2016 criteria. * refractory or relapsed after initial remission, or stage iii-iv de novo patients * pet/ct or ct/mri with at least one objectively evaluable lesion. * general status ecog score 0-3 points. * the laboratory test within 1 week before enrollment meets the following conditions: blood routine: hb\>80g/l, plt\>50×10e9/l. liver function: alt, ast, tbil ≤2 times the upper limit of normal. renal function: cr is normal. cardiac function: lvef≥50%, ecg does not suggest any acute myocardial infarction, arrhythmia or atrioventricular conduction above i blocking. * sign the informed consent form exclusion criteria: active infection requires icu treatment. concomitant hiv infection or active infection with hbv, hcv. patients who are infected with hbv but not active hepatitis at the same time are notexcluded. significant organ dysfunction pregnant and lactating women. had a history of autoimmune diseases, and disease was active in the last 6 months. those who were known to be allergic to drugs in the study regimen. patients with other tumors who require surgery or chemotherapy within 6 months. • other experimental drugs are being used.
a study to determine the improvement of the symptoms of benign prostatic hyperplasia (bph) when switching subjects from proscar to avodart

Conditions: Benign Prostatic Hyperplasia

Summary: hypothesis: dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on international prostate symptom score,and lower pvr based on the scientific information that dutasteride inhibits both type i and ii 5-alpha-reducatase vs. finasteride which only inhibits the type ii enzyme


Eligibility criteria:
inclusion criteria: * male * age 50-80 * on finasteride for no less than 12 months * willing to undergo all necessary test in the 12 month evaluation exclusion criteria: * history of medication non-compliance * unwillingness to undergo/tolerate 2 blood draws * unwillingness to tolerate/undergo 2 trusp

Keywords: bph
the zambia ivermectin trial for the treatment and prevention of covid-19

Conditions: SARS-CoV-2; Ivermectin

Summary: the study aims to test whether ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in icu and transition probabilities to icu (ventilator).

with the onset of global pandemic of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and the sharp rise in infection and mortality rates, efficient management of the current medical emergency has become an absolute priority. a lot of resources have been directed to developing a comprehensive therapeutic approach to preventing and curing this disease, and this has mostly been in western countries. however, lack of definite treatment, high number of infected people, limited capacity and the impact of covid-19 on existing health infrastructure has left biomedical researchers and clinicians faced with the mammoth task of providing appropriate clinical care solutions and strategies with favorable cost-benefit outcomes, which can help in both curbing the disease and treating patients. to meet this challenge, repurposing of available drugs has become vital. evidence from several recent clinical trials on the effects of available therapeutic clinical drugs and vitamin supplements on mortality rate and other clinical outcomes associated with covid-19 are promising, however, the efficacy, safety, and appropriate dosing of therapeutic clinical drugs such as ivermectin, remain largely unevaluated in sub-saharan africa. the investigators propose to evaluate and compare the efficacy of ivermectin in the management of covid-19.

Eligibility criteria:
inclusion criteria: * individuals diagnosed positive for sars-cov-2 by real-time reverse transcription pcr (rrt-pcr with presence of a fever, cough, and/or sore throat. exclusion criteria: * patients will be excluded if they report to be allergic to ivermectin or if there is potential for a drug-drug interaction with ivermectin; * have chronic illnesses (e.g., ischemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease); * have received ivermectin in the last 7 days; are pregnant or lactating; * or have participated in any other clinical trial within the last month.
association of functional comt val108/met polymorphism with smoking cessation in nicotine replacement therapy

Conditions: Nicotine Dependence

Summary: nicotine replacement treatment (nrt) can be efficacious for smoking cessation, but used by only a minority of smokers in china. pharmacogenetic matching may improve treatment outcomes for nrt in subgroups of smokers. the investigators evaluated the efficacy and safety of sublingual nicotine tablets (snt) for smoking cessation and the association of catechol-o-methyltransferase (comt) genotype with efficacy in this smoking cessation trial among chinese smokers.

all subjects provided written informed consent after a full explanation of the protocol design.

Eligibility criteria:
inclusion criteria: * subjects motivated to stop smoking and han chinese * aged 20-70 years who lived in the haidian district of beijing * smoke ≥10 cigarettes/day * have smoked for ≥3 years * carbon monoxide (co) level ≥10 p.p.m. in exhaled air exclusion criteria: * a history of "diagnostic and statistical manual of mental disorders-fourth edition" (dsm-iv) psychiatric disorder * alcohol abuse and other drug abuse * with pathological changes in the floor of their mouth * cardiovascular disease * taking psychotropic medications * using other forms of tobacco or any other nrt products during the last 6 months * pregnant or breast-feeding
the nacho trial (nut allergy children oit)

Conditions: Oral Immunotherapy for Food Allergy; Tree Nut Allergy; Cashew Nut Allergy

Summary: most food allergies that begin in early childhood are mild and resolve by school age, but nut allergies persist in about 80-90% of individuals into adulthood. the consumption of nuts, particularly cashew nuts, has increased dramatically in finland in the 21st century, leading to a rise in severe allergic reactions to cashew nuts among young children. of the food anaphylaxis cases reported in the finnish anaphylaxis registry between 2015-2020, 49% were caused by nuts, with cashew nuts being the most common trigger. the standard treatment for nut allergies is strict avoidance of nuts and symptom management with emergency medications. oral immunotherapy (oit) is a food allergy treatment that increases tolerance, and it has primarily been studied in school-aged children, with desensitization achieved in about 80% of cases. permanent tolerance, depending on the allergen, develops in 30-50% of cases within five years. international guidelines recommend peanut oit for children over the age of 4 who have severe peanut allergies. the likelihood of achieving tolerance, especially permanent tolerance, appears to improve the earlier the treatment is started. to date, only one study (nuit cracker) has been published on cashew nut desensitization in children over 4 years old, involving 50 children, where 88% achieved desensitization to both cashew nuts and pistachios. the aim of this study is to develop a cashew nut desensitization protocol and investigate its effectiveness in achieving tolerance and permanent desensitization in children aged 1-17 years, compared to cashew nut avoidance. the study will assess the safety of cashew nut desensitization and its impact on the quality of life of patients and their families.


Eligibility criteria:
inclusion criteria: 1. age 6 months - 17 years 2. sensitization to cashew nut (allergen-specific ige or positive skin prick test) 3. positive oral food challenge for cashew nut exclusion criteria: 1. poor adherence 2. uncontrolled or severe asthma 3. uncontrolled active or severe or atopic dermatitis 4. chronic urticaria 5. eosinophilic esophagitis or other gastrointestinal eosinophilic disorders 6. active malignant neoplasia 7. active systemic, autoimmune disease 8. diabetes treated with insulin 9. severe systemic illness or severe medical conditions such as cardiovascular or lung diseases 10. medication with beta blockers 11. medication with ace-inhibitors 12. mastocytosis 13. pregnancy or breastfeeding 14. language barriers (not fluent finnish or swedish)

Keywords: oral immunotherapy cashew tree nut food allergen immunotherapy